sulfonylurea

sulfonylurea
Class identifier	Sulfonylurea
Use	Type 2 diabetes
ATC prefix	A10
ATC suffix	BB
Biological target	ATP-sensitive potassium channel

sulfonylurea. Sulfonylureas are a class of antidiabetic medication primarily used in the management of type 2 diabetes mellitus. They function by stimulating insulin release from the pancreatic beta cells of the islets of Langerhans. First discovered in the 1940s, these agents have been a cornerstone of oral hypoglycemic therapy for decades, though their use has evolved with the advent of newer drug classes.

Mechanism of action

Sulfonylureas exert their primary effect by binding to the sulfonylurea receptor subunit of the ATP-sensitive potassium channel on the membrane of pancreatic beta cells. This binding causes the channel to close, inhibiting the efflux of potassium ions and leading to depolarization of the cell membrane. Subsequent opening of voltage-gated calcium channels allows an influx of calcium ions, which triggers the exocytosis of insulin granules from intracellular stores. The process is dependent on the presence of functional beta cells and is most effective in the presence of glucose. Research into this mechanism was significantly advanced by scientists at the Joslin Diabetes Center and institutions like the University of Chicago.

Medical uses

The primary indication for sulfonylureas is as a second-line agent for type 2 diabetes when metformin monotherapy is insufficient or contraindicated, as per guidelines from the American Diabetes Association and the European Association for the Study of Diabetes. They are used to lower glycated hemoglobin levels and manage postprandial hyperglycemia. Their use is generally avoided in patients with type 1 diabetes or diabetic ketoacidosis due to the absence of functional beta cells. They have also been investigated, though not primarily used, in certain forms of neonatal diabetes related to mutations in genes like KCNJ11.

Adverse effects

The most common and significant adverse effect is hypoglycemia, which can be severe and prolonged, particularly with long-acting agents like glibenclamide. This risk is heightened in the elderly, those with renal impairment, or during periods of caloric restriction. Other effects include weight gain, gastrointestinal upset, and skin reactions such as photosensitivity or rash. Rare but serious effects include hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion and possible adverse cardiovascular outcomes, a concern highlighted by studies like the University Group Diabetes Program.

Drug interactions

The hypoglycemic effect of sulfonylureas can be potentiated by many drugs, increasing the risk of severe hypoglycemia. Notable interacting agents include sulfonamide antibiotics, warfarin, nonsteroidal anti-inflammatory drugs like phenylbutazone, fluconazole, and angiotensin-converting enzyme inhibitors. Conversely, their glucose-lowering effect can be antagonized by drugs such as thiazide diuretics, corticosteroids, phenytoin, and isoniazid. The metabolism of many sulfonylureas via the cytochrome P450 system, particularly CYP2C9, is a major site for these interactions.

History

The discovery of sulfonylureas began in the 1940s with the observation that certain sulfonamide antibiotics used for treating typhoid fever caused hypoglycemia. This led researchers at Montpellier University and later the University of Berlin to investigate related compounds. The first-generation agent tolbutamide was introduced in the 1950s by Hoechst AG, following work by scientists like Auguste Loubatières. Second-generation agents like glipizide and glibenclamide, developed by companies including Pfizer and Boehringer Mannheim, offered increased potency. Their role was shaped by major clinical trials such as the United Kingdom Prospective Diabetes Study.

Examples

First-generation sulfonylureas include tolbutamide, discovered by Hoechst AG, and chlorpropamide. Second-generation agents, which are more commonly used, include glibenclamide (known as glyburide in the United States and Canada), glipizide (developed by Pfizer), gliclazide (common in the United Kingdom and Japan), and glimepiride. These are marketed under various brand names such as Diabinese, Glynase, Amaryl, and Minodiab. The third-generation agent glimepiride is distinguished by its extra-pancreatic effects.

Category:Antidiabetic drugs Category:Sulfonylureas